Team

NGT BioPharma Consultants Leaders, Professionals and Subject Matter Experts

Our team of biopharmaceutical drug development leaders, industry experts, and strategic thinkers oversees a network of over 180 top-tier consultants whose experience and expertise span the essential drug development disciplines beginning in Late Discovery and encompassing Preclinical and Clinical Development, Commercialization/Launch and Life-Cycle Management.

Michael K. O’Brien, PhD
President & CEO
Mark A. Krook, PhD
Head of Early Drug Development

Mark Buswell, PhD

Head of Digital CMC

Daniel Schaufelberger, PhD

Head of Pediatric Center of Excellence
Roger Nosal, MA
Head of Global Regulatory Strategy and Submissions
Ronay LeBlanc, MA
Head of Quality & Compliance
Jim Weber, PhD
Head of CMC Biologics
Ed Herpel, MA
Head of Business Development
Michelle McGuinness, MS
Head of Non-CMC Regulatory Strategy
Michael Placke, PhD, DABT
Head of Nonclinical Sciences
Lillian Yengi, PhD
PreClinical and Clinical Biomarker Development
Rachel Franckowiak, BA
Head of Administration
Malcolm Berry, PhD - Multi-Stage Continuous Processing for APIs
 
Malcolm Berry, PhD
API Continuous Processing

Nancy C. Motola, PhD, RAC
Regulatory, Compliance, Quality Assurance
Michael Placke, NGT Biopharma Consultants
 
Michael Placke, PhD, DABT
Nonclinical Development
and Drug Safety

Leo Adalbert, NGT BioPharma Consultants

 
Leo J. Adalbert
Principal Consultant –
Strategic Commercialization

 
John L. Dillon, PhD
API Process R&D, Synthetic Organic Chemistry
 
Jeff Brum, PhD
Pharmaceutical Analysis – CMC Product Development

Robert Dennehy, PhD
API Crystallization and Solid State
 
Steve Hammond
Process Analytics and
PAT Innovator
 
Paul E. Luner, PhD
Oral Formulation Development & Physical Pharmaceutics
 
Frank P. Orlowski, MBA
Biotech and Life Sciences
Global Finance
 
Douglas Nesta, PhD
Chemistry, Manufacturing & Controls
 
Mike Webb, PhD
Chemistry, Manufacturing & Controls